Reported Earnings • Aug 20
First quarter 2027 earnings released: JP¥22.36 loss per share (vs JP¥4.69 profit in 1Q 2026) First quarter 2027 results: JP¥22.36 loss per share (down from JP¥4.69 profit in 1Q 2026). Revenue: JP¥258.0m (down 36% from 1Q 2026). Net loss: JP¥91.0m (down JP¥110.0m from profit in 1Q 2026). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance. New Risk • Jun 03
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: JP¥1.59b (US$9.95m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Duyuru • Jun 03
PhoenixBio Co., Ltd. to Report Q1, 2027 Results on Aug 14, 2026 PhoenixBio Co., Ltd. announced that they will report Q1, 2027 results on Aug 14, 2026 Reported Earnings • May 20
Full year 2026 earnings released: EPS: JP¥30.75 (vs JP¥111 loss in FY 2025) Full year 2026 results: EPS: JP¥30.75 (up from JP¥111 loss in FY 2025). Revenue: JP¥1.57b (up 1.6% from FY 2025). Net income: JP¥125.0m (up JP¥573.0m from FY 2025). Profit margin: 8.0% (up from net loss in FY 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance. Duyuru • May 15
PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2026 PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2026. Duyuru • May 10
PhoenixBio Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026 PhoenixBio Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026 Reported Earnings • Feb 16
Third quarter 2026 earnings released: EPS: JP¥19.90 (vs JP¥6.28 loss in 3Q 2025) Third quarter 2026 results: EPS: JP¥19.90 (up from JP¥6.28 loss in 3Q 2025). Revenue: JP¥444.0m (up 25% from 3Q 2025). Net income: JP¥81.0m (up JP¥107.0m from 3Q 2025). Profit margin: 18% (up from net loss in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance. Duyuru • Dec 02
PhoenixBio Co., Ltd. to Report Q3, 2026 Results on Feb 13, 2026 PhoenixBio Co., Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026 Reported Earnings • Nov 19
Second quarter 2026 earnings released: JP¥1.72 loss per share (vs JP¥36.30 loss in 2Q 2025) Second quarter 2026 results: JP¥1.72 loss per share (improved from JP¥36.30 loss in 2Q 2025). Revenue: JP¥356.0m (up 5.0% from 2Q 2025). Net loss: JP¥7.00m (loss narrowed 95% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance. New Risk • Oct 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risk Market cap is less than US$100m (JP¥1.98b market cap, or US$13.0m). Duyuru • Sep 02
PhoenixBio Co., Ltd. to Report Q2, 2026 Results on Nov 14, 2025 PhoenixBio Co., Ltd. announced that they will report Q2, 2026 results on Nov 14, 2025 Reported Earnings • Aug 16
First quarter 2026 earnings released: EPS: JP¥4.69 (vs JP¥5.71 in 1Q 2025) First quarter 2026 results: EPS: JP¥4.69 (down from JP¥5.71 in 1Q 2025). Revenue: JP¥400.0m (down 11% from 1Q 2025). Net income: JP¥19.0m (down 17% from 1Q 2025). Profit margin: 4.8% (down from 5.1% in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance. Duyuru • Jun 03
PhoenixBio Co., Ltd. to Report Q1, 2026 Results on Aug 14, 2025 PhoenixBio Co., Ltd. announced that they will report Q1, 2026 results on Aug 14, 2025 Reported Earnings • May 21
Full year 2025 earnings released: JP¥110 loss per share (vs JP¥6.88 profit in FY 2024) Full year 2025 results: JP¥110 loss per share (down from JP¥6.88 profit in FY 2024). Revenue: JP¥1.54b (down 10% from FY 2024). Net loss: JP¥445.0m (down JP¥471.0m from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year. Duyuru • May 15
PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2025 PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2025. New Risk • Mar 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: JP¥1.49b (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (JP¥1.49b market cap, or US$9.98m). Duyuru • Mar 04
PhoenixBio Co., Ltd. to Report Fiscal Year 2025 Results on May 15, 2025 PhoenixBio Co., Ltd. announced that they will report fiscal year 2025 results on May 15, 2025 Reported Earnings • Feb 16
Third quarter 2025 earnings released: JP¥6.28 loss per share (vs JP¥3.45 loss in 3Q 2024) Third quarter 2025 results: JP¥6.28 loss per share (further deteriorated from JP¥3.45 loss in 3Q 2024). Revenue: JP¥355.0m (down 21% from 3Q 2024). Net loss: JP¥26.0m (loss widened 100% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. New Risk • Feb 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (JP¥1.42b market cap, or US$9.31m). Minor Risk Share price has been volatile over the past 3 months (5.1% average weekly change). Duyuru • Dec 03
PhoenixBio Co., Ltd. to Report Q3, 2025 Results on Feb 14, 2025 PhoenixBio Co., Ltd. announced that they will report Q3, 2025 results on Feb 14, 2025 New Risk • Nov 15
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: JP¥1.46b (US$9.39m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (JP¥1.46b market cap, or US$9.39m). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.4% net profit margin). Shareholders have been diluted in the past year (8.1% increase in shares outstanding). Duyuru • Sep 03
PhoenixBio Co., Ltd. to Report Q2, 2025 Results on Nov 14, 2024 PhoenixBio Co., Ltd. announced that they will report Q2, 2025 results on Nov 14, 2024 Reported Earnings • Aug 18
First quarter 2025 earnings released: EPS: JP¥5.71 (vs JP¥11.56 in 1Q 2024) First quarter 2025 results: EPS: JP¥5.71 (down from JP¥11.56 in 1Q 2024). Revenue: JP¥449.0m (up 2.3% from 1Q 2024). Net income: JP¥23.0m (down 45% from 1Q 2024). Profit margin: 5.1% (down from 9.6% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to JP¥467, the stock trades at a trailing P/E ratio of 72.9x. Average trailing P/E is 22x in the Life Sciences industry in Japan. Total loss to shareholders of 23% over the past three years. Duyuru • Jun 06
PhoenixBio Co., Ltd. to Report Q1, 2025 Results on Aug 13, 2024 PhoenixBio Co., Ltd. announced that they will report Q1, 2025 results on Aug 13, 2024 Reported Earnings • May 21
Full year 2024 earnings released: EPS: JP¥6.88 (vs JP¥145 in FY 2023) Full year 2024 results: EPS: JP¥6.88 (down from JP¥145 in FY 2023). Revenue: JP¥1.72b (down 19% from FY 2023). Net income: JP¥26.0m (down 95% from FY 2023). Profit margin: 1.5% (down from 23% in FY 2023). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Duyuru • May 17
PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2024 PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2024. Duyuru • Mar 03
PhoenixBio Co., Ltd. to Report Fiscal Year 2024 Results on May 15, 2024 PhoenixBio Co., Ltd. announced that they will report fiscal year 2024 results on May 15, 2024 Reported Earnings • Feb 17
Third quarter 2024 earnings released: JP¥3.45 loss per share (vs JP¥10.86 profit in 3Q 2023) Third quarter 2024 results: JP¥3.45 loss per share (down from JP¥10.86 profit in 3Q 2023). Revenue: JP¥447.0m (down 15% from 3Q 2023). Net loss: JP¥13.0m (down 135% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. New Risk • Feb 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (JP¥1.92b market cap, or US$12.8m). Duyuru • Dec 07
PhoenixBio Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024 PhoenixBio Co., Ltd. announced that they will report Q3, 2024 results on Feb 14, 2024 Reported Earnings • Nov 19
Second quarter 2024 earnings released: JP¥4.05 loss per share (vs JP¥76.11 profit in 2Q 2023) Second quarter 2024 results: JP¥4.05 loss per share (down from JP¥76.11 profit in 2Q 2023). Revenue: JP¥442.0m (down 36% from 2Q 2023). Net loss: JP¥15.0m (down 106% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Duyuru • Sep 06
PhoenixBio Co., Ltd. to Report Q2, 2024 Results on Nov 14, 2023 PhoenixBio Co., Ltd. announced that they will report Q2, 2024 results on Nov 14, 2023 Reported Earnings • Aug 17
First quarter 2024 earnings released: EPS: JP¥11.56 (vs JP¥31.15 in 1Q 2023) First quarter 2024 results: EPS: JP¥11.56 (down from JP¥31.15 in 1Q 2023). Revenue: JP¥439.0m (down 1.3% from 1Q 2023). Net income: JP¥42.0m (down 59% from 1Q 2023). Profit margin: 9.6% (down from 23% in 1Q 2023). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Duyuru • Jun 03
PhoenixBio Co., Ltd. to Report Q1, 2023 Results on Aug 14, 2023 PhoenixBio Co., Ltd. announced that they will report Q1, 2023 results on Aug 14, 2023 Reported Earnings • May 19
Full year 2023 earnings released: EPS: JP¥145 (vs JP¥117 loss in FY 2022) Full year 2023 results: EPS: JP¥145 (up from JP¥117 loss in FY 2022). Revenue: JP¥2.12b (up 60% from FY 2022). Net income: JP¥493.0m (up JP¥880.0m from FY 2022). Profit margin: 23% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 16
Third quarter 2023 earnings released: EPS: JP¥10.86 (vs JP¥9.37 loss in 3Q 2022) Third quarter 2023 results: EPS: JP¥10.86 (up from JP¥9.37 loss in 3Q 2022). Revenue: JP¥525.0m (up 77% from 3Q 2022). Net income: JP¥37.0m (up JP¥68.0m from 3Q 2022). Profit margin: 7.0% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Duyuru • Dec 04
PhoenixBio Co., Ltd. to Report Q3, 2023 Results on Feb 14, 2023 PhoenixBio Co., Ltd. announced that they will report Q3, 2023 results on Feb 14, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: JP¥76.11 (vs JP¥58.69 loss in 2Q 2022) Second quarter 2023 results: EPS: JP¥76.11 (up from JP¥58.69 loss in 2Q 2022). Revenue: JP¥690.0m (up 273% from 2Q 2022). Net income: JP¥253.0m (up JP¥447.0m from 2Q 2022). Profit margin: 37% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 2 highly experienced directors. 1 independent director (6 non-independent directors). Independent Outside Director Yoshinori Fujii was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Duyuru • Sep 03
PhoenixBio Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022 PhoenixBio Co., Ltd. announced that they will report Q2, 2023 results on Nov 14, 2022 Reported Earnings • Aug 14
First quarter 2023 earnings released: EPS: JP¥31.15 (vs JP¥19.46 in 1Q 2022) First quarter 2023 results: EPS: JP¥31.15 (up from JP¥19.46 in 1Q 2022). Revenue: JP¥445.0m (down 1.5% from 1Q 2022). Net income: JP¥103.0m (up 61% from 1Q 2022). Profit margin: 23% (up from 14% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Duyuru • Jun 03
PhoenixBio Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022 PhoenixBio Co., Ltd. announced that they will report Q1, 2023 results on Aug 12, 2022 Duyuru • May 18
PhoenixBio Co., Ltd., Annual General Meeting, Jun 28, 2022 PhoenixBio Co., Ltd., Annual General Meeting, Jun 28, 2022. Reported Earnings • May 17
Full year 2022 earnings released: JP¥117 loss per share (vs JP¥73.60 loss in FY 2021) Full year 2022 results: JP¥117 loss per share (down from JP¥73.60 loss in FY 2021). Revenue: JP¥1.32b (up 31% from FY 2021). Net loss: JP¥387.0m (loss widened 63% from FY 2021). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Independent Outside Director Yoshinori Fujii was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Apr 08
PhoenixBio Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022 PhoenixBio Co., Ltd. announced that they will report fiscal year 2022 results on May 13, 2022 Reported Earnings • Feb 16
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: JP¥9.37 loss per share (up from JP¥24.33 loss in 3Q 2021). Revenue: JP¥296.0m (up 48% from 3Q 2021). Net loss: JP¥31.0m (loss narrowed 61% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 15
Second quarter 2022 earnings released: JP¥58.69 loss per share (vs JP¥44.41 loss in 2Q 2021) The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2022 results: Revenue: JP¥185.0m (up 33% from 2Q 2021). Net loss: JP¥194.0m (loss widened 33% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Reported Earnings • May 19
Full year 2021 earnings released: JP¥73.60 loss per share (vs JP¥142 loss in FY 2020) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: JP¥1.01b (down 23% from FY 2020). Net loss: JP¥238.0m (loss narrowed 43% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year whereas the company’s share price has fallen by 17% per year. Duyuru • Mar 04
PhoenixBio Co., Ltd. to Report Fiscal Year 2021 Results on May 14, 2021 PhoenixBio Co., Ltd. announced that they will report fiscal year 2021 results on May 14, 2021 Reported Earnings • Feb 14
Third quarter 2021 earnings released: JP¥24.33 loss per share (vs JP¥9.54 loss in 3Q 2020) The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: JP¥200.0m (down 36% from 3Q 2020). Net loss: JP¥80.0m (loss widened 186% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Dec 22
New 90-day low: JP¥582 The company is down 20% from its price of JP¥727 on 23 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 18% over the same period. Is New 90 Day High Low • Dec 03
New 90-day low: JP¥616 The company is down 9.0% from its price of JP¥679 on 04 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 7.0% over the same period. Duyuru • Sep 06
PhoenixBio Co., Ltd. to Report Q2, 2021 Results on Nov 13, 2020 PhoenixBio Co., Ltd. announced that they will report Q2, 2021 results on Nov 13, 2020 Duyuru • Jun 20
PhoenixBio Co., Ltd. to Report Q1, 2021 Results on Aug 12, 2020 PhoenixBio Co., Ltd. announced that they will report Q1, 2021 results on Aug 12, 2020